MedWatch

Genmab-CEO: Drug could be ready in 2016

The special status given to a candidate drug from Genmab could cut years off the development. The company’s CEO has talked to Medwatch about the future of the company following a number of promising announcements.

Foto: Genmab/PR

Big-spending investors have been ripping Genmab shares of the shelves in the beginning of the year and last week the share went up by another 12 % in one day, following to positive announcements from the company:

The candidate drug Daratumumab gained the coveted Breakthrough Therapy designation from the FDA and the already marketed drug Arzerra performed well in a new combination study.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier